ASCO GI: Improved GIST Survival With Residual Tumor Removal Post-Maintenance Imatinib

Assigning patients with gastrointestinal stromal tumor (GIST) to undergo surgical resection of residual tumor after disease control with maintenance imatinib was beneficial to patient survival, according to the results of a retrospective study presented at the ASCO 2013 Gastrointestinal Cancers Symposium.
Source: Cancer Network - Category: Cancer & Oncology Source Type: news